MicroRNA Expression Signatures Determine Prognosis and Survival in Glioblastoma Multiforme—a Systematic Overview

Molecular Neurobiology

Volumn 50, Issue 3, 2014, Pages 896-913

  Henriksen, Michael ^a   Johnsen, Kasper Bendix ^a   Andersen, Hjalte Holm ^a   Pilgaard, Linda ^a   Duroux, Meg ^a  

^a AALBORG UNIVERSITY   (Denmark)

Author keywords

Glioblastoma multiforme; Glioma; MicroRNA; Prognosis; Signature; Survival

Indexed keywords

MICRORNA;

BRAIN TUMOR; DISEASE COURSE; GENE EXPRESSION PROFILING; GENETICS; GLIOBLASTOMA; HUMAN; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

BRAIN NEOPLASMS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; MICRORNAS; PROGNOSIS; SURVIVAL RATE;

EID: 84895641390     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8668-y     Document Type: Article

References (176)

1. Lima FRS, Kahn SA, Soletti RC et al (2012) Glioblastoma: therapeutic challenges, what lies ahead. Biochim Biophys Acta 1826:338–349. doi:10.1016/j.bbcan.2012.05.004
2. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncol 14(Suppl 5):v1–v49. doi:10.1093/neuonc/nos218
3. Kanu OO, Mehta A, Di C et al (2009) Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets 13:701–718. doi:10.1517/14728220902942348
4. He J, Olson JJ, James CD (1995) Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 55:4833–4836
5. Watanabe K, Tachibana O, Sata K et al (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217–223, discussion 23–4
6. Verhaak RGW, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110. doi:10.1016/j.ccr.2009.12.020
7. Chaudhry NS, Shah AH, Ferraro N et al (2013) Predictors of long-term survival in patients with glioblastoma multiforme: advancements from the last quarter century. Cancer Invest 31:287–308. doi:10.3109/07357907.2013.789899
8. Hegi ME, Diserens A-C, Gorlia T et al (2005) MGMTGene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. doi:10.1056/NEJMoa043331
9. Everhard S, Kaloshi G, Crinière E et al (2006) MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60:740–743. doi:10.1002/ana.21044
10. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773. doi:10.1056/NEJMoa0808710
11. Wang Z, Bao Z, Yan W et al (2013) Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type. J Exp Clin Cancer Res 32:59. doi:10.1186/1756-9966-32-59
12. Lakomy R, Sana J, Hankeova S et al (2011) MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci 102:2186–2190. doi:10.1111/j.1349-7006.2011.02092.x
13. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233. doi:10.1016/j.cell.2009.01.002
14. Lagos-Quintana M (2001) Identification of novel genes coding for small expressed RNAs. Science 294:853–858. doi:10.1126/science.1064921
15. Ørom UA, Nielsen FC, Lund AH (2008) MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 30:460–471. doi:10.1016/j.molcel.2008.05.001
16. Thomson DW, Bracken CP, Goodall GJ (2011) Experimental strategies for microRNA target identification. Nucleic Acids Res 39:6845–6853. doi:10.1093/nar/gkr330
17. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. 75:843–854
18. Pasquinelli AE, Reinhart BJ, Slack F et al (2000) Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408:86–89. doi:10.1038/35040556
19. Reinhart BJ, Slack FJ, Basson M et al (2000) The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403:901–906. doi:10.1038/35002607
20. Calin GA (2006) MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66:7390–7394. doi:10.1158/0008-5472.CAN-06-0800
21. Madrigal-Matute J, Rotllan N, Aranda JF, Fernández-Hernando C (2013) MicroRNAs and atherosclerosis. Curr Atheroscler Rep 15:322. doi:10.1007/s11883-013-0322-z
22. Vickers KC, Rye K-A, Tabet F (2014) MicroRNAs in the onset and development of cardiovascular disease. Clin Sci 126:183–194. doi:10.1042/CS20130203
23. Zhu S, Pan W, Qian Y (2013) MicroRNA in immunity and autoimmunity. J Mol Med 91:1039–1050. doi:10.1007/s00109-013-1043-z
24. Abe M, Bonini NM (2013) MicroRNAs and neurodegeneration: role and impact. Trends Cell Biol 23:30–36. doi:10.1016/j.tcb.2012.08.013
25. Wang Q, Li P, Li A et al (2012) Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res 31:97. doi:10.1186/1756-9966-31-97
26. Winter J, Jung S, Keller S et al (2009) Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 11:228–234. doi:10.1038/ncb0309-228
27. Yi R, Qin Y, Macara IG, Cullen BR (2003) Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. 17:3011–3016. doi:10.1101/gad.1158803
28. Kawamata T, Yoda M, Tomari Y (2011) Multilayer checkpoints for microRNA authenticity during RISC assembly. 12:944–949. doi:10.1038/embor.2011.128
29. Winter J, Diederichs S (2011) MicroRNA biogenesis and cancer. Methods Mol Biol 676:3–22. doi:10.1007/978-1-60761-863-8_1
30. Stoorvogel W (2012) Functional transfer of microRNA by exosomes. Blood 119:646–648. doi:10.1182/blood-2011-11-389478
31. Chen X, Liang H, Zhang J et al (2012) Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell 3:28–37. doi:10.1007/s13238-012-2003-z
32. Lu J, Getz G, Miska EA, et al. (2005) MicroRNA expression profiles classify human cancers. 435:834–838. doi:10.1038/nature03702
33. Calin GA, Ferracin M, Cimmino A et al (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353:1793–1801. doi:10.1056/NEJMoa050995
34. Takamizawa J (2004) Reduced expression of the let-7 MicroRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64:3753–3756. doi:10.1158/0008-5472.CAN-04-0637
35. Yanaihara N, Caplen N, Bowman E et al (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189–198. doi:10.1016/j.ccr.2006.01.025
36. Kim T-M, Huang W, Park R et al (2011) A developmental taxonomy of glioblastoma defined and maintained by microRNAs. Cancer Res 71:3387–3399. doi:10.1158/0008-5472.CAN-10-4117
37. Volinia S, Calin GA, Liu C-G et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103:2257–2261. doi:10.1073/pnas.0510565103
38. Møller HG, Rasmussen AP, Andersen HH et al (2013) A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol 47:131–144. doi:10.1007/s12035-012-8349-7
39. Malzkorn B, Wolter M, Liesenberg F et al (2010) Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 20:539–550. doi:10.1111/j.1750-3639.2009.00328.x
40. Lages E, Guttin A, El Atifi M et al (2011) MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS ONE 6:e20600. doi:10.1371/journal.pone.0020600
41. Ciafre SA, Galardi S, Mangiola A et al (2005) Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334:1351–1358. doi:10.1016/j.bbrc.2005.07.030
42. Lavon I, Zrihan D, Granit A et al (2010) Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro-Oncol 12:422–433. doi:10.1093/neuonc/nop061
43. Li Y, Zhao S, Zhen Y et al (2011) A miR-21 inhibitor enhances apoptosis and reduces G(2)-M accumulation induced by ionizing radiation in human glioblastoma U251 cells. Brain Tumor Pathol 28:209–214. doi:10.1007/s10014-011-0037-1
44. Gabriely G, Würdinger T, Kesari S et al (2008) MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 28:5369–5380. doi:10.1128/MCB.00479-08
45. Dong H, Luo L, Hong S et al (2010) Integrated analysis of mutations, miRNA and mRNA expression in glioblastoma. BMC Syst Biol 4:163. doi:10.1186/1752-0509-4-163
46. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65:6029–6033. doi:10.1158/0008-5472.CAN-05-0137
47. Schramedei K, Mörbt N, Pfeifer G et al (2011) MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Oncogene 30:2975–2985. doi:10.1038/onc.2011.15
48. Zhou X, Ren Y, Moore L et al (2010) Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest 90:144–155. doi:10.1038/labinvest.2009.126
49. Zhou X, Zhang J, Jia Q et al (2010) Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3. Oncol Rep 24:195–201
50. Kwak H-J, Kim Y-J, Chun K-R et al (2011) Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene 30:2433–2442. doi:10.1038/onc.2010.620
51. Zhi F, Chen X, Wang S et al (2010) The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer 46:1640–1649. doi:10.1016/j.ejca.2010.02.003
52. Shi L, Chen J, Yang J et al (2010) MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 1352:255–264. doi:10.1016/j.brainres.2010.07.009
53. Corsten MF, Miranda R, Kasmieh R et al (2007) MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res 67:8994–9000. doi:10.1158/0008-5472.CAN-07-1045
54. Ren Y, Zhou X, Mei M et al (2010) MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 10:27. doi:10.1186/1471-2407-10-27
55. Ren Y, Kang C-S, Yuan X-B et al (2010) Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed 21:303–314. doi:10.1163/156856209X415828
56. Li D, Chen P, Li X-Y et al (2011) Grade-specific expression profiles of miRNAs/mRNAs and docking study in human grade I-III astrocytomas. OMICS 15:673–682. doi:10.1089/omi.2011.0064
57. Chaudhry MA, Sachdeva H, Omaruddin RA (2010) Radiation-induced micro-RNA modulation in glioblastoma cells differing in DNA-repair pathways. DNA Cell Biol 29:553–561. doi:10.1089/dna.2009.0978
58. Li Y, Li W, Yang Y et al (2009) MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 1286:13–18. doi:10.1016/j.brainres.2009.06.053
59. Gaur AB, Holbeck SL, Colburn NH, Israel MA (2011) Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neuro-Oncol 13:580–590. doi:10.1093/neuonc/nor033
60. Silber J, Lim DA, Petritsch C et al (2008) miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6:14. doi:10.1186/1741-7015-6-14
61. Sasayama T, Nishihara M, Kondoh T et al (2009) MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer 125:1407–1413. doi:10.1002/ijc.24522
62. Zhang C, Han L, Zhang A et al (2010) Global changes of mRNA expression reveals an increased activity of the interferon-induced signal transducer and activator of transcription (STAT) pathway by repression of miR-221/222 in glioblastoma U251 cells. Int J Oncol 36:1503–1512
63. Conti A, Aguennouz M, La Torre D et al (2009) miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol 93:325–332. doi:10.1007/s11060-009-9797-4
64. Huse JT, Brennan C, Hambardzumyan D et al (2009) The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 23:1327–1337. doi:10.1101/gad.1777409
65. Guan Y, Mizoguchi M, Yoshimoto K et al (2010) MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res 16:4289–4297. doi:10.1158/1078-0432.CCR-10-0207
66. Rao SAM, Santosh V, Somasundaram K (2010) Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol 23:1404–1417. doi:10.1038/modpathol.2010.135
67. Wuchty S, Arjona D, Li A et al (2011) Prediction of associations between microRNAs and gene expression in glioma biology. PLoS ONE 6:e14681. doi:10.1371/journal.pone.0014681
68. Papagiannakopoulos T, Shapiro A, Kosik KS (2008) MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 68:8164–8172. doi:10.1158/0008-5472.CAN-08-1305
69. Quintavalle C, Donnarumma E, Iaboni M et al (2013) Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. Oncogene 32:4001–4008. doi:10.1038/onc.2012.410
70. Chao T-F, Xiong H-H, Liu W et al (2013) MiR-21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and hMSH2. J Huazhong Univ Sci Technol Med Sci 33:525–529. doi:10.1007/s11596-013-1153-4
71. Delfino KR, Serão NVL, Southey BR, Rodriguez-Zas SL (2011) Therapy-, gender- and race-specific microRNA markers, target genes and networks related to glioblastoma recurrence and survival. Cancer Genomics Proteomics 8:173–183
72. Quant EC, Wen PY (2010) Response assessment in neuro-oncology. Curr Oncol Rep 13:50–56. doi:10.1007/s11912-010-0143-y
73. Reardon DA, Galanis E, DeGroot JF et al (2011) Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncol 13:353–361. doi:10.1093/neuonc/noq203
74. Chinot OL, Macdonald DR, Abrey LE et al (2013) Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep 13:347. doi:10.1007/s11910-013-0347-2
75. Levin VA, Crafts DC, Norman DM et al (1977) Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg 47:329–335. doi:10.3171/jns.1977.47.3.0329
76. Macdonald DR, Cascino TL, Schold SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280
77. Brandsma D, van den Bent MJ (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22:633–638. doi:10.1097/WCO.0b013e328332363e
78. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740. doi:10.1200/JCO.2008.19.8721
79. Hygino da Cruz LC, Rodriguez I, Domingues RC et al (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. Am J Neuroradiol 32:1978–1985. doi:10.3174/ajnr.A2397
80. Chinot OL, Motte Rouge T, Moore N et al (2011) AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 28:334–340. doi:10.1007/s12325-011-0007-3
81. Tao T, Wang Y, Luo H et al (2013) Involvement of FOS-mediated miR-181b/miR-21 signalling in the progression of malignant gliomas. Eur J Cancer 49:3055–3063. doi:10.1016/j.ejca.2013.05.010
82. Ma R, Yan W, Zhang G et al (2012) Upregulation of miR-196b confers a poor prognosis in glioblastoma patients via inducing a proliferative phenotype. PLoS ONE 7:e38096. doi:10.1371/journal.pone.0038096
83. Wu Z, Sun L, Wang H et al (2012) MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma. PLoS ONE 7:e47270. doi:10.1371/journal.pone.0047270
84. Li Y, Xu J, Chen H et al (2013) Comprehensive analysis of the functional microRNA-mRNA regulatory network identifies miRNA signatures associated with glioma malignant progression. Nucleic Acids Res 41:e203. doi:10.1093/nar/gkt1054
85. Gabriely G, Yi M, Narayan RS et al (2011) Human glioma growth is controlled by microRNA-10b. Cancer Res 71:3563–3572. doi:10.1158/0008-5472.CAN-10-3568
86. Guessous F, Alvarado-Velez M, Marcinkiewicz L et al (2013) Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol 112:153–163. doi:10.1007/s11060-013-1047-0
87. Srinivasan S, Patric IRP, Somasundaram K (2011) A ten-microRNA expression signature predicts survival in glioblastoma. PLoS ONE 6:e17438. doi:10.1371/journal.pone.0017438
88. Zinn PO, Sathyan P, Mahajan B et al (2012) A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature. PLoS ONE 7:e41522. doi:10.1371/journal.pone.0041522
89. Bozdag S, Li A, Riddick G et al (2013) Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels. PLoS ONE 8:e62982. doi:10.1371/journal.pone.0062982
90. Zhang W, Zhang J, Hoadley K et al (2012) miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro-Oncol 14:712–719. doi:10.1093/neuonc/nos089
91. Zhang W, Zhang J, Yan W et al (2013) Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer 119:814–824. doi:10.1002/cncr.27826
92. Quintavalle C, Mangani D, Roscigno G et al (2013) MiR-221/222 target the DNA methyltransferase MGMT in glioma cells. PLoS ONE 8:e74466. doi:10.1371/journal.pone.0074466
93. de Biase D, Visani M, Morandi L et al (2012) miRNAs expression analysis in paired fresh/frozen and dissected formalin fixed and paraffin embedded glioblastoma using real-time pCR. PLoS ONE 7:e35596. doi:10.1371/journal.pone.0035596
94. Niyazi M, Zehentmayr F, Niemöller OM et al (2011) MiRNA expression patterns predict survival in glioblastoma. Radiat Oncol 6:153. doi:10.1186/1748-717X-6-153
95. Ilhan-Mutlu A, Wöhrer A, Berghoff AS et al (2013) Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens. J Neurooncol 112:347–354. doi:10.1007/s11060-013-1078-6
96. Zhang C, Zhang J, Hao J et al (2012) High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med 10:119. doi:10.1186/1479-5876-10-119
97. Dews M, Fox JL, Hultine S et al (2010) The myc-miR-17 92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res 70:8233–8246. doi:10.1158/0008-5472.CAN-10-2412
98. Yang G, Zhang R, Chen X et al (2011) MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status. J Mol Med 89:1037–1050. doi:10.1007/s00109-011-0775-x
99. Shi Z-M, Yan Z et al (2012) MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1. PLoS ONE 7:10. doi:10.1371/journal.pone.0032709.g007
100. Vo DT, Qiao M, Smith AD et al (2011) The oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAs. RNA Biol 8:817–828. doi:10.4161/rna.8.5.16041
101. Cui JG, Zhao Y, Sethi P et al (2010) Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation. J Neurooncol 98:297–304. doi:10.1007/s11060-009-0077-0
102. Zhang Y, Chao T, Li R et al (2009) MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J Mol Med 87:43–51. doi:10.1007/s00109-008-0403-6
103. Godlewski J, Nowicki MO, Bronisz A et al (2008) Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68:9125–9130. doi:10.1158/0008-5472.CAN-08-2629
104. Wang X-F, Shi Z-M, Wang X-R et al (2012) MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. J Cancer Res Clin Oncol 138:573–584. doi:10.1007/s00432-011-1114-x
105. Kreth S, Limbeck E, Hinske LC et al (2013) In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing. Acta Neuropathol 125:671–681. doi:10.1007/s00401-013-1081-1
106. Guessous F, Zhang Y, Kofman A et al (2010) microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 9:1031–1036
107. Yin D, Ogawa S, Kawamata N et al (2012) miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene 32:1155–1163. doi:10.1038/onc.2012.132
108. Xia H, Qi Y, Ng SS et al (2009) microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. Brain Res 1269:158–165. doi:10.1016/j.brainres.2009.02.037
109. Katakowski M, Zheng X, Jiang F et al (2010) MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Invest 28:1024–1030. doi:10.3109/07357907.2010.512596
110. Zhang C-Z, Zhang J-X, Zhang A-L et al (2010) MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 9:229. doi:10.1186/1476-4598-9-229
111. Medina R, Zaidi SK, Liu C-G et al (2008) MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res 68:2773–2780. doi:10.1158/0008-5472.CAN-07-6754
112. Wang S, Lu S, Geng S et al (2013) Expression and clinical significance of microRNA-326 in human glioma miR-326 expression in glioma. Med Oncol 30:373. doi:10.1007/s12032-012-0373-y
113. Lu X, Zhao P, Zhang C et al (2009) Analysis of miR-221 and p27 expression in human gliomas. Mol Med Rep 2:651–656. doi:10.3892/mmr_00000152
114. Hao J, Zhang C, Zhang A et al (2012) miR-221/222 is the regulator of Cx43 expression in human glioblastoma cells. Oncol Rep 27:1504–1510. doi:10.3892/or.2012.1652
115. Hui W, Yuntao L, Lun L et al (2013) MicroRNA-195 inhibits the proliferation of human glioma cells by directly targeting cyclin D1 and cyclin E1. PLoS ONE 8:e54932. doi:10.1371/journal.pone.0054932
116. Zhang Q-Q, Xu H, Huang M-B et al (2012) MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neuro-Oncol 14:278–287. doi:10.1093/neuonc/nor216
117. Yang Y, Wu J, Guan H et al (2012) MiR-136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2. FEBS Lett 586:3608–3612. doi:10.1016/j.febslet.2012.08.003
118. Zhong J, Paul A, Kellie SJ, O'Neill GM (2010) Mesenchymal migration as a therapeutic target in glioblastoma. J Oncol 2010:430142. doi:10.1155/2010/430142
119. Tivnan A, McDonald KL (2013) Current progress for the use of miRNAs in glioblastoma treatment. Mol Neurobiol. doi:10.1007/s12035-013-8464-0
120. Griveau A, Bejaud J, Anthiya S et al (2013) Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death. Int J Pharm 454:765–774. doi:10.1016/j.ijpharm.2013.05.049
121. Katakowski M, Buller B, Zheng X et al (2013) Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett 335:201–204. doi:10.1016/j.canlet.2013.02.019
122. Wang W, Dai LX, Zhang S et al (2013) Regulation of epidermal growth factor receptor signaling by plasmid-based microRNA-7 inhibits human malignant gliomas growth and metastasis in vivo. Neoplasma 60:274–283. doi:10.4149/neo_2013_036
123. Liu X, Li G, Su Z et al (2013) Poly(amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells. Oncol Rep 29:1387–1394. doi:10.3892/or.2013.2283
124. Lee Y, El Andaloussi S, Wood MJA (2012) Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet. doi:10.1093/hmg/dds317
125. El Andaloussi S, Mäger I, Breakefield XO, Wood MJA (2013) Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. doi:10.1038/nrd3978
126. Vlassov AV, Magdaleno S, Setterquist R, Conrad R (2012) Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta 1820:940–948. doi:10.1016/j.bbagen.2012.03.017
127. Valadi H, Ekström K, Bossios A et al (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654–659. doi:10.1038/ncb1596
128. Katakowski M, Buller B, Wang X et al (2010) Functional microRNA is transferred between glioma cells. Cancer Res 70:8259–8263. doi:10.1158/0008-5472.CAN-10-0604
129. Alvarez-Erviti L, Seow Y, Yin H et al (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29:341–345. doi:10.1038/nbt.1807
130. Ohno S-I, Takanashi M, Sudo K et al (2012) Systemically injected exosomes targeted to EGFR deliver antitumor MicroRNA to breast cancer cells. Mol Ther. doi:10.1038/mt.2012.180
131. Munoz JL, Bliss SA, Greco SJ et al (2013) Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucleic Acids 2:e126. doi:10.1038/mtna.2013.60
132. Dai D-W, Lu Q, Wang L-X et al (2013) Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM. BMC Cancer 13:478. doi:10.1186/1471-2407-13-478
133. Genovese G, Ergun A, Shukla SA et al (2012) MicroRNA regulatory network inference identifies miR-34a as a novel regulator of TGF- signaling in glioblastoma. Cancer Discov 2:736–749. doi:10.1158/2159-8290.CD-12-0111
134. Haapa-Paananen S, Chen P, Hellström K et al (2013) Functional profiling of precursor microRNAs identifies MicroRNAs essential for glioma proliferation. PLoS ONE 8:e60930. doi:10.1371/journal.pone.0060930
135. Hua Y, Larsen N, Kalyana-Sundaram S et al (2013) miRConnect 2.0: identification of oncogenic, antagonistic miRNA families in three human cancers. BMC Genomics 14:179. doi:10.1186/1471-2164-14-179
136. Lee HK, Bier A, Cazacu S et al (2013) MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS ONE 8:e54652. doi:10.1371/journal.pone.0054652
137. Qiu S, Huang D, Yin D et al (2013) Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme. Biochim Biophys Acta 1832:1697–1707. doi:10.1016/j.bbadis.2013.05.015
138. Qiu S, Lin S, Hu D et al (2013) Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med 11:10. doi:10.1186/1479-5876-11-10
139. Suzuki HI, Mihira H, Watabe T et al (2013) Widespread inference of weighted microRNA-mediated gene regulation in cancer transcriptome analysis. Nucleic Acids Res 41:e62. doi:10.1093/nar/gks1439
140. Wang X-R, Luo H, Li H-L et al (2013) Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN. Neuro-Oncol 15:1491–1501. doi:10.1093/neuonc/not107
141. Xiao Y, Ping Y, Fan H et al (2013) Identifying dysfunctional miRNA-mRNA regulatory modules by inverse activation, cofunction, and high interconnection of target genes: a case study of glioblastoma. Neuro-Oncol 15:818–828. doi:10.1093/neuonc/not018
142. Chang C, Shi H, Wang C et al (2012) Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma. Neurosci Lett 531:204–208. doi:10.1016/j.neulet.2012.10.021
143. Chen L, Han L, Zhang K et al (2012) VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1 /VEGF and -catenin/Tcf-4 signaling. Neuro-Oncol 14:1026–1036. doi:10.1093/neuonc/nos122
144. Gao H, Zhao H, Xiang W (2013) Expression level of human miR-34a correlates with glioma grade and prognosis. J Neurooncol 113:221–228. doi:10.1007/s11060-013-1119-1
145. He J, Deng Y, Yang G, Xie W (2013) MicroRNA-203 down-regulation is associated with unfavorable prognosis in human glioma. J Surg Oncol 108:121–125. doi:10.1002/jso.23315
146. Hermansen SK, Dahlrot RH, Nielsen BS et al (2012) MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. J Neurooncol 111:71–81. doi:10.1007/s11060-012-0992-3
147. Hou S-X, Ding B-J, Li H-Z et al (2013) Identification of microRNA-205 as a potential prognostic indicator for human glioma. J Clin Neurosci 20:933–937. doi:10.1016/j.jocn.2012.10.015
148. Jiang L, Mao P, Song L et al (2010) miR-182 as a prognostic marker for glioma progression and patient survival. Am J Pathol 177:29–38. doi:10.2353/ajpath.2010.090812
149. Jiang J, Sun X, Wang W et al (2012) Tumor microRNA-335 expression is associated with poor prognosis in human glioma. Med Oncol 29:3472–3477. doi:10.1007/s12032-012-0259-z
150. Li G, Zhang Z, Tu Y et al (2013) Correlation of microrna-372 upregulation with poor prognosis in human glioma. Diagn Pathol 8:1. doi:10.1186/1746-1596-8-1
151. Lu S, Wang S, Geng S et al (2012) Upregulation of microRNA-224 confers a poor prognosis in glioma patients. Clin Transl Oncol 15:569–574. doi:10.1007/s12094-012-0972-2
152. Lu S, Wang S, Geng S et al (2012) Increased expression of microRNA-17 predicts poor prognosis in human glioma. J Biomed Biotechnol 2012:1–6. doi:10.1155/2012/970761
153. Speranza MC, Frattini V, Pisati F et al (2012) NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget 3:723–734
154. Sun B, Pu B, Chu D et al (2013) MicroRNA-650 expression in glioma is associated with prognosis of patients. J Neurooncol 115:375–380. doi:10.1007/s11060-013-1243-y
155. Wu Z, Wang L, Li G et al (2013) Increased expression of microRNA-9 predicts an unfavorable prognosis in human glioma. Mol Cell Biochem 384:263–268. doi:10.1007/s11010-013-1805-5
156. Schraivogel D, Weinmann L, Beier D et al (2011) CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBO J 30:4309–4322. doi:10.1038/emboj.2011.301
157. Ernst A, Campos B, Meier J et al (2010) De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. Oncogene 29:3411–3422. doi:10.1038/onc.2010.83
158. Skalsky RL, Cullen BR (2011) Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS ONE 6:e24248. doi:10.1371/journal.pone.0024248
159. Tian RQ, Wang XH, Hou LJ et al (2011) MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis. J Biol Chem 286:25556–25563. doi:10.1074/jbc.M111.221564
160. Zhang Y, Dutta A, Abounader R (2012) The role of microRNAs in glioma initiation and progression. Front Biosci 17:700–712
161. Wu N, Zhao X, Liu M et al (2011) Role of microRNA-26b in glioma development and its mediated regulation on EphA2. PLoS ONE 6:e16264. doi:10.1371/journal.pone.0016264
162. Luan S, Sun L, Huang F (2010) MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251. Arch Med Res 41:67–74. doi:10.1016/j.arcmed.2010.02.007
163. Li Y, Guessous F, Zhang Y et al (2009) MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 69:7569–7576. doi:10.1158/0008-5472.CAN-09-0529
164. Silber J, Jacobsen A, Ozawa T et al (2012) miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS ONE 7:e33844. doi:10.1371/journal.pone.0033844
165. Meng W, Jiang L, Lu L et al (2012) Anti-miR-155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis. Cell Biol Int. doi:10.1042/CBI20100918
166. Zhang J, Han L, Ge Y et al (2010) miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. Int J Oncol 36:913–920
167. Lukiw WJ, Cui JG, Li YY, Culicchia F (2009) Up-regulation of micro-RNA-221 (miRNA-221; chr Xp11.3) and caspase-3 accompanies down-regulation of the survivin-1 homolog BIRC1 (NAIP) in glioblastoma multiforme (GBM). J Neurooncol 91:27–32. doi:10.1007/s11060-008-9688-0
168. Quintavalle C, Garofalo M, Zanca C et al (2012) miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ. Oncogene 31:858–868. doi:10.1038/onc.2011.280
169. Wang X, Han L, Zhang A et al (2011) Adenovirus-mediated shRNAs for co-repression of miR-221 and miR-222 expression and function in glioblastoma cells. Oncol Rep 25:97–105
170. D'Urso PI, D'Urso OF, Storelli C et al (2012) miR-155 is up-regulated in primary and secondary glioblastoma and promotes tumour growth by inhibiting GABA receptors. Int J Oncol. doi:10.3892/ijo.2012.1420
171. Ling N, Gu J, Lei Z et al (2013) MicroRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma. Oncol Rep 30:2111–2118. doi:10.3892/or.2013.2685
172. Li H, Yang BB (2012) Stress response of glioblastoma cells mediated by miR-17-5p targeting PTEN and the passenger strand miR-17-3p targeting MDM2. Oncotarget 3:1653–1668
173. Wang J, Sai K, Chen F-R, Chen Z-P (2013) miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol 72:147–158. doi:10.1007/s00280-013-2180-3
174. Shi Z-M, Wang X-F, Qian X et al (2013) MiRNA-181b suppresses IGF-1R and functions as a tumor suppressor gene in gliomas. RNA 19:552–560. doi:10.1261/rna.035972.112
175. Han L, Yue X, Zhou X et al (2012) MicroRNA-21 expression is regulated by β-catenin/STAT3 pathway and promotes glioma cell invasion by direct targeting RECK. CNS Neurosci Ther 18:573–583. doi:10.1111/j.1755-5949.2012.00344.x
176. Li W, Guo F, Wang P, et al. (2012) MiR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status. Curr Mol Med 18(7):573–583